Calym Carnot Institute is an academic consortium that provides public-private partnership research in lymphoma and is based out of Paris, France.
The group is formed of 20 multidisciplinary and complementary research entities in the lymphoma field, including The Lymphoma Study Association, and The Lymphoma Academic Research Organisation.
By partnering with Embleema, the research network gains access to its end-to-end data platform services, which include the ability to recruit patients online, to securely collect data for studies, and the ability to use blockchain technology to create an audit trail of participants’ consent.
According to the partners, the aim is to create a patient-centric research network, which is able to ensure data transparency, security and accessibility.
The services include its ‘Hive’ big data and bioinformatics platform, which is used by the US Food and Drug Administration (FDA) for defining evidence generation standards in cell and gene therapy.
Embleema outlines that HIVE is a cloud-based, regulatory analytics platform for genomic and biomarker data, which can be used for support when filing with regulatory authorities.
Both partners aim to focus their individual expertise on creating precision medicines to treat lymphoma.
The ways in which the collaboration could help achieve this goal is by improving recruitment and retention, making consent frameworks for secondary use of data more transparent, and being able to navigate regulatory requirements for multi-omics-based therapies.
“Patients are at the center of all medical research projects. Data transparency, security and accessibility are key concerns. It is a privilege to partner with Embleema to build the next generation trusted patient centered network with all stakeholders involved in our research programs,” says Emmanuel Gomez, General Manager of CALYM.
Last year, Embleema formed a similar partnership with the Epilepsy Foundation, alongside Eisai, to provide a technology platform to capture clinical and real-world patient data.
At the time, the partners said that the platform would allow clinicians and researchers to better interpret data gathered to deliver insights to researchers and to provide personalized digital services to the patients themselves.